Post-earnings recap
Reported
Wed, May 2, 2012
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Neurocrine Biosciences reported a slight loss in EPS, which was below expectations. Despite this, the stock rose by 2.08%, likely due to investor optimism about future growth strategies. The lack of revenue data and guidance may leave some investors cautious, but the stock's positive reaction suggests confidence in the company's direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.01 | N/A | -400.00% |
| Revenue | N/A | N/A | N/A |
Management expressed concern over the recent EPS results but emphasized their commitment to long-term strategies. They did not provide specific guidance for future quarters.
Management acknowledged challenges in meeting expectations for EPS.
Focus remains on long-term growth despite current financial hurdles.